← Back to searchRecruitingRecruiting
A Study of LY3938577 in Participants With Type 2 Diabetes Previously Treated With Basal Insulin
NCT07215312 · Eli Lilly and Company
In plain English
Click the button to translate this study into plain language — what it is, who qualifies, and what participation looks like.
Official title
A Phase 2, Randomized, Open-Label, Comparator-Controlled Trial to Evaluate the Efficacy and Safety of LY3938577 in Study Participants, With Type 2 Diabetes Previously Treated With Basal Insulin
About this study
The purpose of this study is to see how well LY3938577 works and how safe it is compared to degludec in people with type 2 diabetes. Participation in the study will last about 26 weeks.
Eligibility criteria
Inclusion Criteria:
* Have type 2 diabetes
* Are receiving ≥20 units of basal insulin per day and ≤55 units/day and ≤1.5 units/kg/day at screening
* Have hemoglobin A1c (HbA1c) 7.5% to 10.5% inclusive
* Have a body mass index (BMI) of 20 or higher and less than 35 kilograms per square meter (kg/m2)
Exclusion Criteria:
* Have type 1 diabetes
Study design
Enrollment target: 100 participants
Allocation: randomized
Masking: none
Age groups: adult, older_adult
Timeline
Starts: 2025-10-13
Estimated completion: 2026-12
Last updated: 2026-04-17
Interventions
Drug: LY3938577Drug: Degludec
Primary outcomes
- • Change from Baseline in Glucose Time in Range Between 70 and 180 mg/dL Inclusive (Non-Inferiority Analysis) (Baseline through Week 20)
Sponsor
Eli Lilly and Company · industry
Contacts & investigators
ContactTrial questions or participation questions: 1-877-CTLILLY (1-877-285-4559) or · contact · LillyTrials@Lilly.com · 317-615-4559
ContactPhysicians interested in becoming principal investigators please contact · contact · clinical_inquiry_hub@lilly.com
InvestigatorCall 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 8 AM - 8 PM Eastern time (UTC/GMT - 5 hours, EST) · study_director, Eli Lilly and Company
All locations (26)
Tucson Clinical Research InstituteRecruiting
Tucson, Arizona, United States
Encompass Clinical ResearchRecruiting
Spring Valley, California, United States
University Clinical Investigators, Inc.Recruiting
Tustin, California, United States
Tampa Bay Medical ResearchRecruiting
Clearwater, Florida, United States
Encore Medical ResearchRecruiting
Hollywood, Florida, United States
Clinical Research of Central FloridaRecruiting
Lakeland, Florida, United States
Encore Medical Research - WestonRecruiting
Weston, Florida, United States
Iowa Diabetes and Endocrinology Research CenterRecruiting
West Des Moines, Iowa, United States
Washington University School of MedicineRecruiting
St Louis, Missouri, United States
Accellacare - WilmingtonRecruiting
Wilmington, North Carolina, United States
AMR ClinicalRecruiting
Norman, Oklahoma, United States
Tribe Clinical Research, LLCRecruiting
Greenville, South Carolina, United States
Holston Medical GroupRecruiting
Bristol, Tennessee, United States
Texas Diabetes & Endocrinology, P.A.Recruiting
Austin, Texas, United States
Velocity Clinical Research, DallasRecruiting
Dallas, Texas, United States
Juno ResearchRecruiting
Houston, Texas, United States
Southern Endocrinology AssociatesRecruiting
Mesquite, Texas, United States
Consano Clinical Research, LLCRecruiting
Shavano Park, Texas, United States
Texas Valley Clinical ResearchRecruiting
Weslaco, Texas, United States
Chrysalis Clinical ResearchRecruiting
St. George, Utah, United States
Cicemo SrlRecruiting
Buenos Aires, Argentina
CIPRECRecruiting
Buenos Aires, Argentina
Mautalen Salud e InvestigaciónRecruiting
Buenos Aires, Argentina
Centro Medico Dra. Laura Maffei- Investigacion Clinica AplicadaRecruiting
Buenos Aires, Argentina
Instituto CentenarioRecruiting
CABA, Argentina
Instituto Médico Catamarca IMECRecruiting
Rosario, Argentina